Breast cancer patients' experiences on endocrine therapy: Monitoring with a checklist for patients on endocrine therapy (C-PET)

Breast

Volumn 13, Issue 5, 2004, Pages 363-368

  Malinovszky, Kathy M ^a   Cameron, D ^b   Douglas, S ^b   Love, C ^b   Leonard, T ^b   Dixon, J M ^b   Hopwood, P ^c   Leonard, R C F ^a  

^a SINGLETON HOSPITAL   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Communication; Endocrine therapy; Side effects

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; FORMESTANE; GOSERELIN; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL PROTOCOL; COMMUNICATION AID; CONSULTATION; CONTROLLED STUDY; DIZZINESS; DRUG ERUPTION; DYSPNEA; FATIGUE; FEMALE; FLUID RETENTION; HAIR LOSS; HOT FLUSH; HUMAN; IRRITABILITY; JOINT STIFFNESS; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MEDICAL RECORD; METASTASIS; NAUSEA; PATIENT MONITORING; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; SIDE EFFECT; SWEATING; SYMPTOMATOLOGY; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VISUAL DISORDER; WEIGHT GAIN;

EID: 9244233892     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2004.02.009     Document Type: Article

References (12)

1. Ganz P.A. Impact of tamoxifen adjuvant therapy on symptoms, functioning and quality of life J Natl Cancer Inst Monogr 30 2001 130-134
2. Leonard R.C.F. Ray A. Lee L. Leonard T. Hopwood P. Tamoxifen toleration and toxicity Endocr Relat Cancer 4 1997 245-249
3. Leonard R.C.F. Lee L. Harrison M.E. Impact of side-effects associated with endocrine treatments for advanced breast cancer: Clinicians' and patients' perception Breast 5 1996 259-264
4. Fellowes D. Fallowfield L. Saunders C. Houghton J. Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for "well-tolerated" treatments? Breast Cancer Res Treat 66 2001 73-81
5. Adlard J.W. Campbell J. Bishop J.M. Dodwell D.J. Morbidity of tamoxifen-perceptions of patients and healthcare professionals Breast 11 2002 335-339
6. Hopwood P. Living with advanced breast cancer: Development and application of a clinical checklist for patients on endocrine therapy Breast 7 1998 14-21
7. Hopwood P. A checklist for patients on endocrine therapy Eur J Cancer Care 5 suppl. 3 1996 7-8
8. Köhler U. Tolerability of endocrine treatment for advanced breast cancer: Results of an international survey Oncology 54 suppl. 2 1997 23-26
9. Fallowfield L.J. Leaity S.K. Howell A. Benson S. Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine subscale for the FACT-B Breast Cancer Res Treat 55 1999 189-199
10. Coster S. Fallowfield L. The impact of endocrine therapy on patients with breast cancer: A review of the literature Breast 11 2002 1-12
11. Donnellan P. Douglas S. Cameron D. Leonard R.C.F. Aromatase inhibitors and arthralgia J Clin Oncol 19 2001 2767
12. Fallowfield L.J. Fleissig A. Edwards R. et al. , Tamoxifen for the prevention of breast cancer: Psychological impact on women participating in 2 randomised controlled trials J Clin Oncol 19 2001 1885-1892